Saturday, July 18, 2026
Preview mode — showing bulk-ingested data not yet promoted to production. Hide preview

TGA / PMDA / NMPA · Asia-Pacific

somapacitan — TGA / PMDA / NMPA regulatory status

somapacitan (SOGROYA) regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.

Status snapshot

Status
NMPA clinical trials
Brand
SOGROYA
Mechanism
Growth hormone receptor agonist
Target
Growth hormone receptor
Structured fields
6

Pharmacology context used for competitive intelligence: Growth hormone receptor agonist. Target: Growth hormone receptor. This page is a status aggregation for professional reference — not prescribing advice.

Regional decision snapshot — NMPA: clinical trials.

Linked evidence on this spoke: 5 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
NMPA China clinical trials Evidence

Linked clinical programs

Program Phase Sponsor NCT
NN8640-4263 Phase 3 NovoThirteen 2023-506829-11-00
NN8640-4467 Phase 3 NovoThirteen 2023-506927-27-00
Somapacitan Phase 3 Novo Nordisk A/S NCT03811535, NCT04970654
somapacitan Phase 3 Novo Nordisk A/S NCT02229851
NN8640-4245 Phase 2 NovoThirteen 2023-506830-66-00

Related hubs

FAQ

What is the TGA / PMDA / NMPA approval status of somapacitan?

somapacitan currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get somapacitan regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to somapacitan?

This spoke lists 5 published programs associated with somapacitan in our pipeline index.